GRIFOLS

Grifols' net profit rose 33% in the first quarter of 2008 to 31.1 million euros

- ***Revenue for the first three months of 2008 amounted to 201.7 million euros, 10.9% more than in the same period in 2007.***

- ***EBITDA, with the sales margin widening to 29.5%, climbed 30% to 59.5 million euros.***

- ***Grifols' natural hedge against exchange rate risk allowed it to offset exchange rate issues.***

Barcelona, 14 May 2008.- Grifols, a Spanish holding company specialising in the pharmaceutical-hospital industry and a world leader in the production of plasma derivatives, earned revenue of 201.7 million euros in the first quarter of 2008, an increase of 10.9% from the same period a year earlier. Continued positive performance, in both sales volume and prices, of some of the leading plasma derivatives sold by the group, such as albumin and intravenous immunoglobulin, along with a good showing at the Hospital Division, drove the earnings increase. Stripping out the exchange rate effect, revenue would have climbed 17.1%. Nevertheless, Grifols' natural hedge against exchange rate risk largely allowed it to offset negative exchange rate effects from dollar-denominated sales with purchases of plasma, the company's main raw material, which are also in dollars.

Operating expenses amounted to 24% of total sales, similar to a year earlier. **EBITDA** rose 30% year on year to 59.5 million euros vs. 45.8 million euros in the same period in 200, far exceeding the increase in sales.

Net profit in the first quarter of 2008 climbed 33% year on year to 31.1 million euros.

Grifols' debt stood at 380.1 million euros to March 2008, or 2 times EBITDA, compared with 2.2 times EBITDA in 2007.

These earnings reflect the performance of a non-cyclical industry in which demand is continually on the increase and in which Grifols has significant competitive advantages thanks to its plasma collection and fractionation capacity, which the company will continue to expand in coming years.

GRIFOLS

Revenue performance by division:

- **Bioscience** remains the standout division in terms of growth, posting revenue of 149.2 million euros, a year-on-year increase of 22.9%.
- ***Diagnostic*** earned revenue of over 20 million euros. This represents a 4% decrease from a year earlier, although the trend began to change at the end of the quarter. This fall is due to the monthly distribution of some transactions, an effect which will be offset on a cumulative basis in later quarters. Turnover at the Hospital division rose 16.6% on 2007 to 21 million euros. Hospital Logistics drove sales at this division, with an increase of 55,9%.
- Turnover at the ***Raw Materials & Others*** division dropped to 11.1 million euros, in line with company expectations. This division includes sales of intermediate products and raw material (plasma) to third parties. Following its cancellation in the first quarter of 2007 of a contract it had acquired with the PlasmaCare purchase, the company no longer sells plasma directly to competitors.

First quarter 2008 figures:

(millions of euros)	Q1 2008	% 2008 / 2007
Total Revenue:	**201.7**	**+10.8%**
Bioscience Division	149.2	+22.9%
Diagnostic Division	20.3	-4%
Hospital Division	21.0	+16.6%
Raw Materials	11.1	- 47.6%
EBITDA	**59.5**	**+30%**
% of turnover	**29.5%**	
Net Profit	**31.1**	**+33%**
% of turnover	**15.4%**	

Main events in the quarter:

The main initiatives carried out in the first quarter show that Grifols is properly rolling out its 400 million-euro investment plan, whose targets focus both on raising plasma collection capacity and continually increasing plasma derivative production capacity at the company's manufacturing plants:

- **Grifols joins the IBEX-35**
- **Purchase of Novartis' 31,000m^2 former industrial complex in Parets del Vallés** (Barcelona), where the company plans, among other things, to locate the group logistic area.

GRIFOLS

- **Agreement with Stough Development Corporation to open 10 new plasma collection centres in the US over the next 18 months.** The deal will be fully financed by Stough Development Corporation as the owner and lessor of these centres, which will be operated under lease by Grifols. When they come on stream, they will give the group access to an additional 400,000 litres of plasma for fractionation, without its having to use its own funds.

About Grifols

Grifols is a Spanish holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Since 2006, the company has been listed on the Spanish Continuous Market and forms part of the Ibex-35. Currently it is the first company in the European sector in plasma derivatives and the fourth in production worldwide. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, thanks to recent investments and those which will be carried out in 2008-2012, representing 400 million euros. In terms of raw materials, Grifols has ensured its plasma supply with 77 plasmapheresis centres in the United States and in terms of fractionation, its plants in Barcelona (Spain) and Los Angeles (United States) will allow the company to respond to the growing market demand. Nevertheless, the company is preparing for sustained growth in the following 8-10 years and has launched an ambitious investment plan.